BIOTECHNOLOGY FUND

Ironwood Pharmaceuticals, Inc. — Class A* 72,533	
Catalyst Pharmaceuticals, Inc.* 49,729	
Amgen, Inc. 25,911 \$ 6,963,840	\$ 698,493
Gilead Sciences, Inc. Vertex Pharmaceuticals, Inc.* 13,479 4,687,187 Regeneron Pharmaceuticals, Inc.* 5,693 4,685,111 Corteva, Inc. 68,596 3,509,371 Biogen, Inc.* 13,457 3,458,584 Moderna, Inc.* 31,430 3,246,405 Seagen, Inc.* 14,995 3,181,189 Horizon Therapeutics plc* 18,070 2,480,650 BioMarin Pharmaceuticals, Inc.* 12,825 2,271,308 Royalty Pharma plc — Class A 76,578 2,078,327 Sarepta Therapeutics Corp.* 30,841 1,781,685 United Therapeutics Corp.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS ^{††,2} - 0.6%	581,332
Vertex Pharmaceuticals, Inc.* 13,479 4,687,187 Total Pharmaceuticals Regeneron Pharmaceuticals, Inc.* 5,693 4,685,111 HEALTHCARE-PRODUCTS - 2.9% Corteva, Inc. 68,596 3,509,371 Exact Sciences Corp.* 27,755 Biogen, Inc.* 13,457 3,458,584 Natera, Inc.* 25,453 Moderna, Inc.* 31,430 3,246,405 Natera, Inc.* 70tal Healthcare-Products Seagen, Inc.* 14,995 3,181,189 HEALTHCARE-SERVICES - 1.1% Illumina, Inc.* 18,070 2,480,650 Medpace Holdings, Inc.* 4,842 BioMarin Pharmaceutical, Inc.* 12,825 2,271,308 (Cost \$55,028,898) Fotal Common Stocks Royalty Pharma plc — Class A 76,578 2,078,327 Total Common Stocks (Cost \$55,028,898) Facer \$4,000 Amount Incyte Corp.* 30,841 1,781,685 Amount Amount Amount Ionis Pharmaceuticals, Inc.* 6,892 1,556,696 REPURCHASE AGREEMENTS ††,2 - 0.6% Amount Amount	323,332
Regeneron Pharmaceuticals, Inc.* 5,693 4,685,111 Corteva, Inc. 68,596 3,509,371 Exact Sciences Corp.* 27,755 27,755 Exact Sciences Corp.* 27,755 27,755 Exact Sciences Corp.* 27,755 27,755 Exact Sciences Corp.* 27,755 27,755 27,808 27,81,189	21,816,757
Corteva, Inc. Biogen, Inc.* Biogen, Inc.* Moderna, Inc.* Seagen, Inc.* Horizon Therapeutics plc* Illumina, Inc.* BioMarin Pharmaceuticals, Inc.* Royalty Pharma plc — Class A Royalty Pharma plc — Class A Incyte Corp.* Inc	
Biogen, Inc.* 13,457 3,458,584 Natera, Inc.* 25,453	- 000 446
Moderna, Inc.* Seagen, Inc.* Seagen, Inc.* Seagen, Inc.* Horizon Therapeutics plc* Illumina, Inc.* BioMarin Pharmaceuticals, Inc.* Royalty Pharma plc — Class A Incyte Corp.* Incyte Cor	1,893,446
Seagen, Inc.* 14,995 3,181,189 Horizon Therapeutics plc* 25,334 2,930,890 HEALTHCARE-SERVICES - 1.1% Illumina, Inc.* 18,070 2,480,650 Medpace Holdings, Inc.* 4,842 Health Care-Products Medpace Holdings, Inc.* Medpace Holdings, Inc.* 4,842 Health Care-Products 4,842 Hea	1,126,295
Horizon Therapeutics plc* 25,334 2,930,890 HEALTHCARE-SERVICES - 1.1%	3,019,741
Illumina, Inc.* 18,070 2,480,650 Medpace Holdings, Inc.* 4,842	
BioMarin Pharmaceutical, Inc.* 26,119 2,311,009 Alnylam Pharmaceuticals, Inc.* 12,825 2,271,308 Royalty Pharma plc — Class A 76,578 2,078,327 Sarepta Therapeutics, Inc.* 15,464 1,874,546 Incyte Corp.* 30,841 1,781,685 United Therapeutics Corp.* 6,892 1,556,696 Ionis Pharmaceuticals, Inc.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS*†,2 - 0.6%	1,172,393
Alnylam Pharmaceuticals, Inc.* 12,825 2,271,308 Royalty Pharma plc — Class A 76,578 2,078,327 Sarepta Therapeutics, Inc.* 15,464 1,874,546 Incyte Corp.* 30,841 1,781,685 United Therapeutics Corp.* 6,892 1,556,696 Ionis Pharmaceuticals, Inc.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS*†,2 - 0.6%	1,172,333
Royalty Pharma plc — Class A 76,578 2,078,327 Sarepta Therapeutics, Inc.* 15,464 1,874,546 Incyte Corp.* 30,841 1,781,685 United Therapeutics Corp.* 6,892 1,556,696 Ionis Pharmaceuticals, Inc.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS*†,2 - 0.6%	
Sarepta Therapeutics, Inc.* 15,464 1,874,546 Incyte Corp.* 30,841 1,781,685 United Therapeutics Corp.* 6,892 1,556,696 Ionis Pharmaceuticals, Inc.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS*†,2 - 0.6%	103,898,392
Incyte Corp.* 30,841 1,781,685 Амоинт United Therapeutics Corp.* 6,892 1,556,696 Амоинт Ionis Pharmaceuticals, Inc.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS ^{††,2} - 0.6%	
United Therapeutics Corp.* 6,892 1,556,696 Ionis Pharmaceuticals, Inc.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS ^{††,2} - 0.6%	
Ionis Pharmaceuticals, Inc.* 33,371 1,513,709 Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS ^{††,2} - 0.6%	
Exelixis, Inc.* 67,625 1,477,606 REPURCHASE AGREEMENTS ^{††,2} - 0.6 %	
,	
Argenx SE ADR* 2,792 1,372,631 J.P. Morgan Securities LLC	
Halozyme Therapeutics, Inc.* 33,480 1,278,936 issued 09/29/23 at 5.30%	
CRISPR Therapeutics AG* 27,329 1,240,463 due 10/02/23 \$ 367,031	367,031
BioNTech SE ADR* 11,189 1,215,573 Barclays Capital, Inc.	
ImmunoGen, Inc.* 72,205 1,145,893 issued 09/29/23 at 5.29%	
Amicus Therapeutics, Inc.* 87,004 1,057,969 due 10/02/23 142,574	142,574
Insmed, Inc.* 41,844 1,056,561 BofA Securities, Inc.	
Apellis Pharmaceuticals, Inc.* 27,700 1,053,708 issued 09/29/23 at 5.30%	
Mirati Therapeutics, Inc.* 23,632 1,029,410 due 10/02/23 141,166	141,166
Guardant Health, Inc.* 30,961 917,684 Total Repurchase Agreements	
Arrowhead Pharmaceuticals, Inc.* 32,836 882,303 (Cost \$650,771)	650,771
Karuna Therapeutics, Inc.* 5,104 863,035	
Intellia Therapeutics, Inc.* 27,155 858,641 S HARES	
Cytokinetics, Inc.* 28,921 852,013	-
Blueprint Medicines Corp.* 16,675 837,419 SECURITIES LENDING COLLATERAL ^{†,3} - 0.3%	
ACADIA Pharmaceuticals, Inc.* 38,965 812,031 Money Market Fund	
Ultragenyx Pharmaceutical, Inc.* 22,422 799,344 First American Government	
Denali Therapeutics, Inc.* 36,904 761,330 Obligations Fund - Class X, 5.26% ⁴ 313,928	313,928
Beam Therapeutics, Inc.* 30,154 /25,204	
BioCryst Pharmaceuticals, Inc.* 95,227 674,207 Total Securities Lending Collateral Prothers Corporation ple* (Cost \$313,928)	212 020
Frotilella Corporation pic 15,285 040,505	313,928
Twist Bioscience Corp.* 27,842 564,079 Total Investments - 100.4 %	
TG Therapeutics, Inc.* 63,154 527,967 (Cost \$55,993,597)	\$ 104,863,091
Vir Biotechnology, Inc.* 55,138 516,643 Other Assets & Liabilities, net - 10 41%	(374,418)
PTC Inerapeutics, Inc.* 22,803 511,015	\$ 104,488,673
Novavax, Inc.*,1 57,330 415,069 Total Net Assets - 100.0%	\$ 10 4 ,400,075
Total Biotechnology 77,889,501	
PHARMACEUTICALS - 20.9%	
AbbVie, Inc. 61,485 9,164,954	
AstraZeneca plc ADR 45,792 3,101,034	
Viatris, Inc. 196,801 1,940,458	
Neurocrine Biosciences, Inc.* 17,078 1,921,275	
Jazz Pharmaceuticals plc* 12,127 1,569,719	
Alkermes plc* 51,027 1,429,266	
Vaxcyte, Inc.* 21,320 1,086,894	

BIOTECHNOLOGY FUND

- * Non-income producing security.
- † Value determined based on Level 1 inputs.
- †† Value determined based on Level 2 inputs.
- ¹ All or a portion of this security is on loan at September 30, 2023.
- ² Repurchase Agreements.
- ³ Securities lending collateral.
- $^{\rm 4}$ Rate indicated is the 7-day yield as of September 30, 2023.

ADR — American Depositary Receipt

plc — Public Limited Company